Vanguard Group’s NewAmsterdam Pharma NAMS Stock Holding History

Vanguard Group’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$6.07M	Buy	172,956 +490	+0.3%	+$17.8K	﹤0.01%	3178
2025 Q3	$4.9M	Sell	172,466 -6,380	-4%	-$153K	﹤0.01%	3289
2025 Q2	$3.24M	Buy	178,846 +148,370	+487%	+$2.71M	﹤0.01%	3361
2025 Q1	$624K	Hold	30,476	–	–	﹤0.01%	3832
2024 Q4	$783K	Buy	30,476 +17,031	+127%	+$362K	﹤0.01%	3829
2024 Q3	$223K	Hold	13,445	–	–	﹤0.01%	4117
2024 Q2	$258K	Buy	+13,445	New	+$270K	﹤0.01%	4131

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group's NAMS Position: Q4 2025 in Review

Vanguard Group increased its NewAmsterdam Pharma (NAMS) stake by 0.28% in Q4 2025, buying an estimated $17.8K and bringing the position to 172,956 shares worth $6.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3178.

Vanguard Group first reported a position in NAMS in Q2 2024 and has held it in 7 quarters since. 186 funds tracked by Wall St. Rank hold NAMS as of Q4 2025.

Vanguard Group held 172,956 shares of NewAmsterdam Pharma worth $6.07M as of Q4 2025.
Vanguard Group bought 490 NewAmsterdam Pharma shares in Q4 2025, an estimated $17.8K.
NewAmsterdam Pharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3178 holding.
Vanguard Group first reported a position in NewAmsterdam Pharma in Q2 2024 and has held it in 7 quarters since.
186 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.